Special Issue "Sulfonamides"
Deadline for manuscript submissions: closed (1 March 2017)
Prof. Dr. Claudiu T. Supuran
Neurofarba Department, Sezione di Scienze Farmaceutiche e Nutraceutiche, Università degli Studi di Firenze, Sesto Fiorentino (Florence) 50019, Italy
Website | E-Mail
Interests: drug design; metalloenzymes; carbonic anhydrases; anticancer agents; antiinfectives; sulfonamides; coumarins
The primary sulfonamide moiety is present in many clinically used drugs, such as diuretics (furosemide, indapamide, chlorthalidone, thiazides), carbonic anhydrase (CA) inhibitors (CAIs, e.g., acetazolamide, dichlorophenamide, dorzolamide and brinzolamide, SLC-0111, an antitumor agent used in Phase I clinical trials); antiepileptics (zonisamide and sulthiame), the antipsychotic sulpiride, or the cycloxygenase 2 (COX2) inhibitors celecoxib, valdecoxib and palmecoxib. Recently, novel drugs incorporating this group were launched, for example, pazopanib. A large number of sulfonamides possessing various other pharmacologic applications were identified. Secondary and tertiary sulphonamides, as well as sulphonamide isosteres (sulfamides, sulfamates, etc.) are also present in a variety of biologically active compounds. This privileged structural motif will probably be utilized in other drugs in the future. This Special Issue of Molecules is dedicated to compounds from all these structural classes, which have the presence of primary, secondary or tertiary sufonamide moieties in common, as well as their isosteres.
Claudiu T. Supuran
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All papers will be peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Molecules is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 1800 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
- carbonic anhydrase inhibitor
- antiglaucoma drug
- antitumor agent
- cancer diagnostic tool
- cyclooxygenase 2 inhibitor
- receptor tyrosine kinase inhibitor